Stock listing
LSE:IMM ImmuPharma plc Share Price
Home listing (LSE) of ImmuPharma plc
Follow ImmuPharma plc into a list and get an email when it puts out news.
Share price · LSE:IMM
2.90p GBX (pence) +0.33 (+13.1%)
Close on Nov 20, 2026
- Day range
- 2.48p – 3.45p GBX (pence)Nov 20, 2026
- Volume
- 4.22M sharesNov 20, 2026
- Market cap
- £18.10M GBPAt the close on Nov 20, 2026 · price × 625.3M shares outstanding
- 52-week range
- 2.48p – 11.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £84,715 GBPMedian day 1.88M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:IMM · Home | 2.895p GBX (pence) | +0.335 (+13.1%) | 4,218,875 | 2.70p | 3.445p | 2.477p | 2.56p | Close on Nov 20, 2026 |
| Frankfurt:25I | €0.015 EUR | +0.005 (+50.0%) | — | €0.0090 | €0.015 | €0.0090 | €0.010 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:IMM · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.895p | +0.335 | +13.1% | 2.70p | 3.445p | 2.477p | 4,218,875 | |
| 2.56p | -0.09 | -3.4% | 2.605p | 2.993p | 2.555p | 989,369 | |
| 2.65p | +0.05 | +1.9% | 2.615p | 2.84p | 2.505p | 2,186,688 | |
| 2.60p | -0.22 | -7.8% | 2.745p | 3.101p | 2.555p | 2,170,690 | |
| 2.82p | +0.135 | +5.0% | 2.65p | 2.975p | 2.633p | 3,202,469 | |
| 2.685p | -0.275 | -9.3% | 2.88p | 3.106p | 2.549p | 8,311,309 | |
| 2.96p | -0.17 | -5.4% | 3.62p | 3.62p | 2.835p | 3,740,258 | |
| 3.13p | -0.105 | -3.2% | 3.345p | 3.528p | 3.105p | 1,112,860 | |
| 3.235p | -0.055 | -1.7% | 3.325p | 3.511p | 3.212p | 3,679,555 | |
| 3.29p | +0.285 | +9.5% | 3.20p | 3.774p | 3.005p | 8,536,266 | |
| 3.005p | -0.25 | -7.7% | 3.34p | 3.499p | 3.005p | 2,359,338 | |
| 3.255p | -0.265 | -7.5% | 3.435p | 3.985p | 3.225p | 1,878,240 | |
| 3.52p | +0.205 | +6.2% | 3.205p | 3.77p | 3.146p | 4,371,039 | |
| 3.315p | +0.065 | +2.0% | 3.335p | 3.822p | 3.248p | 2,219,850 | |
| 3.25p | -0.65 | -16.7% | 3.85p | 4.47p | 3.102p | 3,967,235 | |
| 3.90p | +0.225 | +6.1% | 3.90p | 4.30p | 3.60p | 1,684,830 | |
| 3.675p | -0.325 | -8.1% | 3.90p | 4.48p | 3.627p | 1,281,721 | |
| 4.00p | +0.35 | +9.6% | 3.76p | 4.00p | 3.511p | 1,301,035 | |
| 3.65p | -0.15 | -3.9% | 3.705p | 4.10p | 3.511p | 514,272 | |
| 3.80p | +0.10 | +2.7% | 3.67p | 4.30p | 3.662p | 944,142 | |
| 3.70p | -0.015 | -0.4% | 4.00p | 4.485p | 3.515p | 1,189,073 | |
| 3.715p | -0.385 | -9.4% | 4.00p | 4.485p | 3.70p | 6,693,244 | |
| 4.10p | +0.10 | +2.5% | 4.15p | 4.485p | 4.00p | 1,858,460 | |
| 4.00p | +0.15 | +3.9% | 4.49p | 4.49p | 3.80p | 1,962,645 | |
| 3.85p | +0.15 | +4.1% | 3.895p | 4.495p | 3.60p | 2,063,786 | |
| 3.70p | -0.105 | -2.8% | 3.80p | 4.50p | 3.70p | 2,125,270 | |
| 3.805p | -0.025 | -0.7% | 3.805p | 4.50p | 3.80p | 889,917 | |
| 3.83p | -0.27 | -6.6% | 4.00p | 4.50p | 3.772p | 3,128,646 | |
| 4.10p | +0.10 | +2.5% | 4.00p | 4.90p | 4.00p | 9,933,604 | |
| 4.00p | +0.70 | +21.2% | 3.78p | 4.50p | 3.27p | 7,845,707 | |
| 3.30p | +0.015 | +0.5% | 3.42p | 3.90p | 3.28p | 1,746,870 | |
| 3.285p | -0.135 | -3.9% | 3.795p | 3.98p | 3.28p | 4,608,114 | |
| 3.42p | +0.145 | +4.4% | 3.34p | 3.795p | 3.25p | 4,540,917 | |
| 3.275p | -0.025 | -0.8% | 3.38p | 3.795p | 3.275p | 818,143 | |
| 3.30p | -0.195 | -5.6% | 3.25p | 3.795p | 3.25p | 2,991,041 | |
| 3.495p | +0.245 | +7.5% | 3.423p | 3.60p | 3.25p | 1,178,422 | |
| 3.25p | -0.005 | -0.2% | 3.25p | 3.795p | 3.199p | 1,988,517 | |
| 3.255p | -0.045 | -1.4% | 3.25p | 3.79p | 3.25p | 666,272 | |
| 3.30p | +0.03 | +0.9% | 3.795p | 3.80p | 3.25p | 738,007 | |
| 3.27p | +0.065 | +2.0% | 3.21p | 3.80p | 3.21p | 1,039,763 | |
| 3.205p | -0.775 | -19.5% | 3.37p | 3.975p | 3.205p | 1,601,816 | |
| 3.98p | +0.32 | +8.7% | 3.43p | 3.98p | 3.20p | 930,776 | |
| 3.66p | -0.145 | -3.8% | 3.50p | 3.66p | 3.265p | 1,641,088 | |
| 3.805p | +0.425 | +12.6% | 3.46p | 3.965p | 3.30p | 1,845,298 | |
| 3.38p | -0.60 | -15.1% | 3.98p | 3.98p | 3.281p | 2,337,142 | |
| 3.98p | +0.485 | +13.9% | 3.975p | 3.98p | 3.21p | 1,159,175 | |
| 3.495p | +0.29 | +9.0% | 3.495p | 3.50p | 3.205p | 1,411,436 | |
| 3.205p | -0.295 | -8.4% | 3.50p | 3.60p | 3.022p | 3,799,660 | |
| 3.50p | -0.10 | -2.8% | 3.69p | 4.10p | 3.50p | 1,447,106 | |
| 3.60p | +0.065 | +1.8% | 3.65p | 4.10p | 3.51p | 740,213 | |
| 3.535p | -0.365 | -9.4% | 4.10p | 4.10p | 3.50p | 1,941,686 | |
| 3.90p | -0.20 | -4.9% | 3.70p | 4.10p | 3.50p | 1,012,684 | |
| 4.10p | +0.10 | +2.5% | 3.848p | 4.10p | 3.60p | 867,503 | |
| 4.00p | +0.40 | +11.1% | 3.70p | 4.10p | 3.60p | 2,327,204 | |
| 3.60p | +0.14 | +4.0% | 3.405p | 3.90p | 3.302p | 3,904,034 | |
| 3.46p | -0.045 | -1.3% | 3.64p | 3.985p | 3.46p | 1,851,045 | |
| 3.505p | -0.075 | -2.1% | 3.50p | 3.99p | 3.50p | 928,203 | |
| 3.58p | +0.08 | +2.3% | 3.985p | 3.985p | 3.405p | 1,900,137 | |
| 3.50p | 0.00 | 0.0% | 3.475p | 3.795p | 3.40p | 2,391,530 | |
| 3.50p | -0.245 | -6.5% | 3.60p | 3.75p | 3.40p | 2,412,650 | |
| 3.745p | +0.335 | +9.8% | 3.55p | 3.75p | 3.405p | 879,758 | |
| 3.41p | +0.005 | +0.1% | 3.52p | 3.985p | 3.40p | 1,929,507 | |
| 3.405p | -0.585 | -14.7% | 4.085p | 4.155p | 3.405p | 1,369,071 | |
| 3.99p | +0.24 | +6.4% | 3.55p | 3.99p | 3.405p | 1,249,004 | |
| 3.75p | +0.06 | +1.6% | 3.985p | 3.985p | 3.40p | 651,132 |
- Ticker
- LSE:IMM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Sep 15, 2026
New peer-reviewed publication
Latest earnings call · Mar 20, 2026
ImmuPharma (LSE:IMM) — Corporate Update
Replay and transcript
Calls
Replays
ImmuPharma (LSE:IMM) — Corporate Update
Fri, Mar 20, 2026 · 8:00 AM ET
Watch TranscriptImmuPharma (LSE:IMM) — Investor Presentation
Thu, Aug 04, 2022 · 7:00 AM ET
Watch TranscriptImmuPharma (LSE:IMM) — Annual General Meeting
Mon, Jun 28, 2021 · 5:30 AM ET
Watch Transcript
Latest news
New peer-reviewed publication
Sep 15, 2026
Closed 3.21p (-8.4%) on Sep 15, 2026
Bioanalytical CRO partner for Kapiglucagon
Aug 10, 2026
Closed 3.73p (-6.9%) on Aug 10, 2026
Thermo Fisher CDMO selected for Kapiglucagon pro
Jul 22, 2026
Closed 4.20p (-6.7%) on Jul 22, 2026
2026 Result of annual general meeting
Jun 25, 2026
Closed 3.70p (-6.8%) on Jun 25, 2026
University of Murcia research relating to P140
Jun 24, 2026
Closed 3.97p (-3.2%) on Jun 24, 2026
Incanthera plc – Corporate Update & Board Changes
Jun 4, 2026
Closed 4.43p (-3.7%) on Jun 4, 2026
FINAL RESULTS for the twelve months ended 31 December 2025
May 27, 2026
Closed 4.31p (-4.3%) on May 27, 2026
IMM initiatesIND-Enabling Program for Kapiglucagon
May 5, 2026
Closed 4.00p (-3.4%) on May 5, 2026
Holding(s) in Company
Apr 10, 2026
Closed 4.95p (-1.8%) on Apr 10, 2026
Chairman’s Open Letter to Shareholders
Apr 9, 2026
Closed 5.04p (+8.4%) on Apr 9, 2026
Financings
Private placement of ordinary shares (Lanstead subscription)
Apr 9, 2026 · US$8.06M
Update: £6M
Buyers: Lanstead (£6 million subscription)
Use of proceeds: Strengthen balance sheet, pursue P140 partnering and fund the accelerated Kapiglucagon development program
Ordinary shares (WRAP retail offering)
Apr 9, 2026 · US$628,639
Update: £468,000
Warrant exercise of warrants over new ordinary shares
Sep 17, 2025 · US$34,150
Closed: £25,000 raised · £0.05 a share
Private placement of new ordinary shares
Feb 13, 2025 · US$1.29M
Announced: £1.03M · GBX 3.75 a share · Stanford Capital Partners Limited
Dealers: Stanford Capital Partners Limited
Use of proceeds: Further investment in the P140 autoimmune platform, strengthening the balance sheet ahead of licensing talks, general working capital and fundraise costs
Strategic investment of new ordinary shares with sharing agreement
Feb 13, 2025 · US$2.35M
Announced: £1.88M · GBX 3.75 a share · Stanford Capital Partners Limited
Dealers: Stanford Capital Partners Limited
Buyers: Lanstead Capital Investors L.P (£1.875 million subscription for 50,000,000 new Ordinary Shares)
Insiders: Lanstead's participation constitutes a related party transaction under the AIM Rules
Use of proceeds: Further investment in the P140 autoimmune platform, strengthening the balance sheet ahead of licensing talks, general working capital and fundraise costs
Decks
Investor Presentation (September 2023)
Investor deck · 31 slides · September 2023
Investor Presentation (January 2022)
Investor deck · 22 slides · January 2022
Investor Presentation (April 2020)
Investor deck · 15 slides · April 2020
Investor Presentation (June 2017)
Investor deck · 30 slides · Jun 30, 2017
ImmuPharma plc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 290 in all · newest Sep 15, 2026 · oldest 1999
- Calls
- 3 calls with a replay · 3 with a transcript · latest Mar 20, 2026
- Decks
- 5 decks · latest September 2023
Where ImmuPharma plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:IMM · Home listing · This page | LSE | United Kingdom | GBX |
| LS Exchange:A0BMC4 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0BMC4 | Lang & Schwarz | Germany | EUR |
| gettex:25I | gettex | Germany | EUR |
| Frankfurt:25I | Frankfurt | Germany | EUR |
| Turquoise:IMML | Turquoise | United Kingdom | GBX |
| AQUIS:IMM.GB | AQUIS | United Kingdom | GBX |
| Munich:25I | Munich | Germany | EUR |
| Stuttgart:25I | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about ImmuPharma plc.